Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma

McClellan M. Walther, Richard B. Alexander, Gary H. Weiss, David Venzon, Arlene Berman, Harvey I. Pass, W. Marston Linehan, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

From May 1985 to December 1990, 93 patients with the clinical diagnosis of metastatic renal cell carcinoma and their primary tumor in place were evaluated for cytoreductive surgery as preparation for systemic therapy with regimens based on interleukin-2. These patients had typical sites of metastatic disease and manifestations of paraneoplastic syndromes. Patients underwent removal of the primary tumor, as well as debulking when this could be performed safely. Thirty-two percent of patients ( 30 93) had a second surgical resection in addition to their nephrectomy, frequently because of the large size of the primary tumor and its invasion of adjacent structures. Thirteen percent of patients ( 12 93) experienced postoperative complications. There were no perioperative mortalities. Forty percent of patients (37/93) who underwent nephrectomy could not be treated with immunotherapy, usually because of progression of disease. A preoperative ECOG status greater than or equal to 2 was the only significant risk factor associated with failure to undergo immunotherapy (P = 0.043). The response rate to immunotherapy in the 56 patients receiving interleukin-2 was 27 percent (4 CR, 11 PR).

Original languageEnglish (US)
Pages (from-to)250-257
Number of pages8
JournalUrology
Volume42
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Immunotherapy
Nephrectomy
Therapeutics
Paraneoplastic Syndromes
Neoplasms
Disease Progression
Mortality

ASJC Scopus subject areas

  • Urology

Cite this

Walther, M. M., Alexander, R. B., Weiss, G. H., Venzon, D., Berman, A., Pass, H. I., ... Rosenberg, S. A. (1993). Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology, 42(3), 250-257. https://doi.org/10.1016/0090-4295(93)90612-E

Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. / Walther, McClellan M.; Alexander, Richard B.; Weiss, Gary H.; Venzon, David; Berman, Arlene; Pass, Harvey I.; Linehan, W. Marston; Rosenberg, Steven A.

In: Urology, Vol. 42, No. 3, 1993, p. 250-257.

Research output: Contribution to journalArticle

Walther, MM, Alexander, RB, Weiss, GH, Venzon, D, Berman, A, Pass, HI, Linehan, WM & Rosenberg, SA 1993, 'Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma', Urology, vol. 42, no. 3, pp. 250-257. https://doi.org/10.1016/0090-4295(93)90612-E
Walther, McClellan M. ; Alexander, Richard B. ; Weiss, Gary H. ; Venzon, David ; Berman, Arlene ; Pass, Harvey I. ; Linehan, W. Marston ; Rosenberg, Steven A. / Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. In: Urology. 1993 ; Vol. 42, No. 3. pp. 250-257.
@article{2463bef7caab44c28ee79e01f813917c,
title = "Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma",
abstract = "From May 1985 to December 1990, 93 patients with the clinical diagnosis of metastatic renal cell carcinoma and their primary tumor in place were evaluated for cytoreductive surgery as preparation for systemic therapy with regimens based on interleukin-2. These patients had typical sites of metastatic disease and manifestations of paraneoplastic syndromes. Patients underwent removal of the primary tumor, as well as debulking when this could be performed safely. Thirty-two percent of patients ( 30 93) had a second surgical resection in addition to their nephrectomy, frequently because of the large size of the primary tumor and its invasion of adjacent structures. Thirteen percent of patients ( 12 93) experienced postoperative complications. There were no perioperative mortalities. Forty percent of patients (37/93) who underwent nephrectomy could not be treated with immunotherapy, usually because of progression of disease. A preoperative ECOG status greater than or equal to 2 was the only significant risk factor associated with failure to undergo immunotherapy (P = 0.043). The response rate to immunotherapy in the 56 patients receiving interleukin-2 was 27 percent (4 CR, 11 PR).",
author = "Walther, {McClellan M.} and Alexander, {Richard B.} and Weiss, {Gary H.} and David Venzon and Arlene Berman and Pass, {Harvey I.} and Linehan, {W. Marston} and Rosenberg, {Steven A.}",
year = "1993",
doi = "10.1016/0090-4295(93)90612-E",
language = "English (US)",
volume = "42",
pages = "250--257",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma

AU - Walther, McClellan M.

AU - Alexander, Richard B.

AU - Weiss, Gary H.

AU - Venzon, David

AU - Berman, Arlene

AU - Pass, Harvey I.

AU - Linehan, W. Marston

AU - Rosenberg, Steven A.

PY - 1993

Y1 - 1993

N2 - From May 1985 to December 1990, 93 patients with the clinical diagnosis of metastatic renal cell carcinoma and their primary tumor in place were evaluated for cytoreductive surgery as preparation for systemic therapy with regimens based on interleukin-2. These patients had typical sites of metastatic disease and manifestations of paraneoplastic syndromes. Patients underwent removal of the primary tumor, as well as debulking when this could be performed safely. Thirty-two percent of patients ( 30 93) had a second surgical resection in addition to their nephrectomy, frequently because of the large size of the primary tumor and its invasion of adjacent structures. Thirteen percent of patients ( 12 93) experienced postoperative complications. There were no perioperative mortalities. Forty percent of patients (37/93) who underwent nephrectomy could not be treated with immunotherapy, usually because of progression of disease. A preoperative ECOG status greater than or equal to 2 was the only significant risk factor associated with failure to undergo immunotherapy (P = 0.043). The response rate to immunotherapy in the 56 patients receiving interleukin-2 was 27 percent (4 CR, 11 PR).

AB - From May 1985 to December 1990, 93 patients with the clinical diagnosis of metastatic renal cell carcinoma and their primary tumor in place were evaluated for cytoreductive surgery as preparation for systemic therapy with regimens based on interleukin-2. These patients had typical sites of metastatic disease and manifestations of paraneoplastic syndromes. Patients underwent removal of the primary tumor, as well as debulking when this could be performed safely. Thirty-two percent of patients ( 30 93) had a second surgical resection in addition to their nephrectomy, frequently because of the large size of the primary tumor and its invasion of adjacent structures. Thirteen percent of patients ( 12 93) experienced postoperative complications. There were no perioperative mortalities. Forty percent of patients (37/93) who underwent nephrectomy could not be treated with immunotherapy, usually because of progression of disease. A preoperative ECOG status greater than or equal to 2 was the only significant risk factor associated with failure to undergo immunotherapy (P = 0.043). The response rate to immunotherapy in the 56 patients receiving interleukin-2 was 27 percent (4 CR, 11 PR).

UR - http://www.scopus.com/inward/record.url?scp=0027182965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027182965&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(93)90612-E

DO - 10.1016/0090-4295(93)90612-E

M3 - Article

C2 - 8379024

AN - SCOPUS:0027182965

VL - 42

SP - 250

EP - 257

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -